Momenta Phamaceuticals (MNTA) Tops Q4 EPS by 6c

Momenta Phamaceuticals, Inc. (NASDAQ: MNTA) reported Q4 EPS of ($0.35), $0.06 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $12.7 million versus the consensus estimate of $10.41 million. Momenta Phamaceuticals, Inc. reaffirmed FY2013 guidance.

For earnings history and earnings-related data on Momenta Phamaceuticals, Inc. (MNTA) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
• Is the global equity rally broadening? UBS weighs in